Department of Experimental Medicine, Sapienza University, Rome, Italy.
J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40. Moreover, mutational screening for TP53 and IDH1 was performed in 27 of 43 cases. The prognostic stratification for histological grading showed no difference in overall (OS) and progression-free survival (PFS) between glioblastomas and anaplastic astrocytomas. Overexpression of YKL40 was detected in 25 of 43 (58%) cases, but YKL-40 expression was not prognostic in terms of OS and PFS. p53 protein expression was observed in 13 of 43 (31%) cases but was not prognostic. TP53 mutations were detected in five of 27 (18%) cases (four glioblastomas and one anaplastic astrocytoma). Patients with TP53 mutation had a shorter median OS (9 months) and PFS (8 months) than those without mutations (OS, 17 months; PFS, 16 months), although this trend did not reach statistical significance (p = 0.07). IDH1 mutations were not detected in any of the cases analyzed. Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent. These observations support the concept that, despite identical histological features, the biology of high-grade gliomas in children differs from that in adults, and therefore different prognostic factors are needed.
本研究的目的是在 43 例儿科高级别胶质瘤(21 例间变性星形细胞瘤 WHO 分级 III 级和 22 例胶质母细胞瘤 WHO 分级 IV 级)中评估组织学分级和 p53、YKL-40 表达的预后价值。此外,对 43 例中的 27 例进行了 TP53 和 IDH1 的突变筛查。组织学分级的预后分层显示,胶质母细胞瘤和间变性星形细胞瘤在总生存期(OS)和无进展生存期(PFS)方面没有差异。在 43 例中的 25 例(58%)检测到 YKL40 过表达,但 YKL-40 表达与 OS 和 PFS 无关。在 43 例中有 13 例(31%)检测到 p53 蛋白表达,但无预后意义。在 27 例中有 5 例(18%)检测到 TP53 突变(4 例胶质母细胞瘤和 1 例间变性星形细胞瘤)。与无突变者相比,TP53 突变患者的中位 OS(9 个月)和 PFS(8 个月)更短(OS,17 个月;PFS,16 个月),尽管这种趋势无统计学意义(p=0.07)。未在分析的任何病例中检测到 IDH1 突变。我们的结果表明,在儿科高级别胶质瘤中:(i)组织学分级没有很强的预后意义,(ii)YKL-40 过表达的频率低于成人高级别胶质瘤,与侵袭性行为无关,(iii)TP53 突变而不是 p53 表达可能与侵袭性行为相关,以及(iv)IDH1 突变不存在。这些观察结果支持这样的概念,即尽管具有相同的组织学特征,但儿童高级别胶质瘤的生物学与成人不同,因此需要不同的预后因素。